Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation

Dabigatran Association With Higher Risk of Acute Coronary Events

(2012) Ken Uchino   ARCHIVES OF INTERNAL MEDICINE

Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial

(2012) Stefan H. Hohnloser et al.   CIRCULATION

Efficacy and Safety of Periprocedural Dabigatran in Patients Undergoing Catheter Ablation of Atrial Fibrillation

(2012) Kenichi Kaseno et al.   CIRCULATION JOURNAL

Should We Recommend Oral Anticoagulation Therapy in Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting With a High HAS-BLED Bleeding Risk Score?

(2012) Juan M. Ruiz-Nodar et al.   Circulation-Cardiovascular Interventions

Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification

(2012) Andreas Clemens et al.   CURRENT MEDICAL RESEARCH AND OPINION

2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: Recommendations for Patient Selection, Procedural Techniques, Patient Management and Follow-up, Definitions, Endpoints, and Research Trial Design: A report of the Heart Rhythm Society (HRS) Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. Developed in partnership with the European Heart Rhythm Association (EHRA), a registered branch of the European Society of Cardiology (ESC) and the European Cardiac Arrhythmia Society (ECAS); and in collaboration with the American College of Cardiology (ACC), American Heart Association (AHA), the Asia Pacific Heart Rhythm Society (APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by the governing bodies of the American College of Cardiology Foundation, the American Heart Association, the European Cardiac Arrhythmia Society, the European Heart Rhythm Association, the Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society, and the Heart Rhythm Society

(2012) H. Calkins et al.   EUROPACE

2012 focused update of the ESC Guidelines for the management of atrial fibrillation

(2012) et al.   EUROPEAN HEART JOURNAL

Acute Ischemic Stroke Treated with Intravenous Tissue Plasminogen Activator in a Patient Taking Dabigatran with Radiographic Evidence of Recanalization

(2012) Navdeep Sangha et al.   Journal of Stroke & Cerebrovascular Diseases

Intravenous Thrombolysis in a Stroke Patient Taking Dabigatran

(2012) Vivien H. Lee et al.   Journal of Stroke & Cerebrovascular Diseases

Safety of Dabigatran Versus Warfarin for Periprocedural Anticoagulation in Patients Undergoing Ablation for Atrial Fibrillation

(2012) Roger A. Winkle et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

New Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes

(2012) Raffaele De Caterina et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used for Stroke Prevention in Atrial Fibrillation

(2012) Gregory Y.H. Lip et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Feasibility and Safety of Dabigatran Versus Warfarin for Periprocedural Anticoagulation in Patients Undergoing Radiofrequency Ablation for Atrial Fibrillation

(2012) Dhanunjaya Lakkireddy et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Dabigatran and risk of myocardial infarction

(2012) John W. Eikelboom et al.   Nature Reviews Cardiology

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation

(2012) Jack Ansell et al.   THROMBOSIS AND HAEMOSTASIS

Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice

(2012) Gregory Y. H. Lip et al.   THROMBOSIS AND HAEMOSTASIS

Risk of Bleeding With 2 Doses of Dabigatran Compared With Warfarin in Older and Younger Patients With Atrial Fibrillation

(2011) John W. Eikelboom et al.   CIRCULATION

Dabigatran Versus Warfarin in Patients With Atrial Fibrillation

(2011) Rangadham Nagarakanti et al.   CIRCULATION

Preventing Cardioembolic Stroke in Atrial Fibrillation with Dabigatran

(2011) Christian Weimar et al.   Current Neurology and Neuroscience Reports

Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure

(2011) Andrea Lee et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

(2011) Manesh R. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Perils of Combination Antithrombotic Therapy and Potential Resolutions

(2011) Marc Fisher et al.   STROKE

Consensus Document: Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting

(2011) John Eikelboom et al.   THROMBOSIS AND HAEMOSTASIS

Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran

(2011) María Consuelo Matute et al.   THROMBOSIS AND HAEMOSTASIS

Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: Similarities and dissimilarities between North America and Europe

(2011) K. Airaksinen et al.   THROMBOSIS AND HAEMOSTASIS

Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation.

(2011) Luciano Crippa et al.   THROMBOSIS AND HAEMOSTASIS

Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review

(2010) Isla M. Ogilvie et al.   AMERICAN JOURNAL OF MEDICINE

Does Warfarin for Stroke Thromboprophylaxis Protect Against MI in Atrial Fibrillation Patients?

(2010) Gregory Y.H. Lip et al.   AMERICAN JOURNAL OF MEDICINE

Risk of Bleeding With Single, Dual, or Triple Therapy With Warfarin, Aspirin, and Clopidogrel in Patients With Atrial Fibrillation

(2010) Morten L. Hansen et al.   ARCHIVES OF INTERNAL MEDICINE

Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in a Stroke Patient Treated with Dabigatran

(2010) Ann De Smedt et al.   CEREBROVASCULAR DISEASES

Dabigatran and Warfarin in Vitamin K Antagonist–Naive and –Experienced Cohorts With Atrial Fibrillation

(2010) Michael D. Ezekowitz et al.   CIRCULATION

Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)

(2010) et al.   EUROPEAN HEART JOURNAL

Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation

(2010) Stephan H. Schirmer et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

EFFECT OF AGE AND RENAL FUNCTION ON THE RISKS OF STROKE AND MAJOR BLEEDING WITH DABIGATRAN COMPARED TO WARFARIN: AN ANALYSIS FROM THE RE-LY STUDY

(2010) Jeff S. Healey et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification

(2010) K. P. CABRAL et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial

(2010) Lars Wallentin et al.   LANCET

Newly Identified Events in the RE-LY Trial

(2010) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

New-onset atrial fibrillation and warfarin initiation: High risk periods and implications for new antithrombotic drugs

(2010) Renato D. Lopes et al.   THROMBOSIS AND HAEMOSTASIS

Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity

(2010) Joachim Stangier et al.   THROMBOSIS AND HAEMOSTASIS

Dabigatran versus Warfarin in Patients with Atrial Fibrillation

(2009) Stuart J. Connolly et al.   NEW ENGLAND JOURNAL OF MEDICINE

New Anticoagulants for Atrial Fibrillation

(2009) Magdalena Sobieraj-Teague et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting

(2009) G. Y. H. Lip et al.   THROMBOSIS AND HAEMOSTASIS

Benefit of Oral Anticoagulant Over Antiplatelet Therapy in Atrial Fibrillation Depends on the Quality of International Normalized Ratio Control Achieved by Centers and Countries as Measured by Time in Therapeutic Range

(2008) Stuart J. Connolly et al.   CIRCULATION

Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran Etexilate

(2008) Joachim Stangier   CLINICAL PHARMACOKINETICS